Persistent androgen receptor (AR) signaling despite low levels of serum androgens has
been identified as a critical target for drug discovery in castration-resistant prostate cancer …

Castration-resistant prostate cancer (CRPC), the invariably lethal phenotype of advanced
prostate cancer, represents a clinical state defined by disease progression despite reduction …

Continued reliance on the androgen receptor (AR) is now understood as a core mechanism
in castration-resistant prostate cancer (CRPC), the most advanced form of this disease …

After decades of limited success in the treatment of castration-resistant prostate cancer
(CRPC), five novel therapeutics were granted Food and Drug Administration regulatory …

Suppression of gonadal androgens by medical or surgical castration remains the mainstay
of treatment for patients with advanced prostate cancer. However, the response to treatment …

What's known on the subject? and What does the study add? Castration resistance has
been appreciated for decades, and several mechanisms theorising on this effect have been …

Second-generation androgen receptor axis-targeted (ARAT) agents, namely abiraterone
and enzalutamide, enable stronger blockade of the androgen receptor (AR) axis and longer …

The discovery of androgen dependence in prostate cancer in 1941 by Huggins and
colleagues has remained the backbone for the treatment of this disease. However, although …

Reactivated androgen receptor (AR) signaling drives castration‐resistant prostate cancer
(CRPC). The novel AR targeting drugs abiraterone and enzalutamide have improved …

The metabolic functions of androgen receptor (AR) in normal prostate are circumvented in
prostate cancer (PCa) to drive tumor growth, and the AR also can acquire new growth …